CCRM
Glenn MacLean has a strong background in research and education, with experience in various roles in the field of technology and venture development. Prior to their current position at CCRM, Glenn worked at Children's Hospital Boston and Harvard Medical School as a Post-Doctoral Fellow, focusing on generating hematopoietic cells from human pluripotent cells to model human disease. Additionally, Glenn also has experience as a Teaching Assistant at Queen's University, where Glenn supervised undergraduate thesis students and taught an "Introduction to Molecular Biology" course to visiting high school students. Glenn holds a PhD in Pathology and Molecular Medicine from Queen's University and a B.Sc (honours) in Biochemistry from McMaster University.
CCRM
1 followers
Regenerative Medicine (RM), which aims to harness the power of stem cells, biomaterials and molecules to repair, regenerate or replace diseased cells, tissues and organs, has the promise to treat, manage and perhaps cure some of the most devastating and costly diseases in the world today. Many new and potentially life-changing RM-based treatments never reach patients because they are not successfully moved from the laboratory to a stage where they can be used in medicine. In order to fulfill RM’s promise to treat the many diseases affecting our population, a world-renowned group of stem cell scientists and engineers have come together to form CCRM, a leader in developing and commercializing regenerative medicine and cell therapy technologies. CCRM formally launched on June 14, 2011. CCRM supports the development and commercialization of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy.